OXBO.F logo

Oxford BioDynamics OTCPK:OXBO.F Stock Report

Last Price

US$0.01

Market Cap

US$4.7m

7D

0%

1Y

-96.0%

Updated

23 Dec, 2024

Data

Company Financials +

Oxford BioDynamics Plc

OTCPK:OXBO.F Stock Report

Market Cap: US$4.7m

OXBO.F Stock Overview

A biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. More details

OXBO.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Oxford BioDynamics Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oxford BioDynamics
Historical stock prices
Current Share PriceUK£0.01
52 Week HighUK£0.15
52 Week LowUK£0.01
Beta0.54
1 Month Change-52.38%
3 Month Changen/a
1 Year Change-96.00%
3 Year Change-97.78%
5 Year Changen/a
Change since IPO-99.12%

Recent News & Updates

Recent updates

Shareholder Returns

OXBO.FUS Life SciencesUS Market
7D0%-2.1%-2.7%
1Y-96.0%-5.5%23.4%

Return vs Industry: OXBO.F underperformed the US Life Sciences industry which returned -5.5% over the past year.

Return vs Market: OXBO.F underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is OXBO.F's price volatile compared to industry and market?
OXBO.F volatility
OXBO.F Average Weekly Movementn/a
Life Sciences Industry Average Movement9.1%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: OXBO.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine OXBO.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200753Jon Anthony Burrowswww.oxfordbiodynamics.com

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.

Oxford BioDynamics Plc Fundamentals Summary

How do Oxford BioDynamics's earnings and revenue compare to its market cap?
OXBO.F fundamental statistics
Market capUS$4.67m
Earnings (TTM)-US$13.97m
Revenue (TTM)US$775.85k

6.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OXBO.F income statement (TTM)
RevenueUK£617.00k
Cost of RevenueUK£361.00k
Gross ProfitUK£256.00k
Other ExpensesUK£11.36m
Earnings-UK£11.11m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.035
Gross Margin41.49%
Net Profit Margin-1,800.32%
Debt/Equity Ratio0%

How did OXBO.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:52
End of Day Share Price 2024/12/09 00:00
Earnings2024/03/31
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford BioDynamics Plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara RaveendranShore Capital Group Ltd
null nullStifel, Equities Research
Christian GlennieStifel, Equities Research